Quantitative, spatial resolution of the epigenetic field effect in prostate cancer
- 30 November 2007
- journal article
- research article
- Published by Wiley in The Prostate
- Vol. 68 (2) , 152-160
Abstract
BACKGROUND: Although a field effect in which transformed cells extend beyond morphologically evident tumor has been proposed in cancer, little direct evidence exists as to its magnitude and spatial resolution. We tested this hypothesis using molecular techniques to detect epigenetic changes in the primary tumor and surrounding tissues.METHODS: Ex vivo core biopsies, each spaced approximately 1 mm apart, were generated from 37 unique prostatectomy samples. The first core biopsy was confirmed to be histologically positive for cancer, and the subsequent biopsies were confirmed to be histologically negative. The methylation ratio of GSTP1, APC, RARβ2, and RASSF1A were measured for all of the 159 cores.RESULTS: No field effect, defined as absence of epigenetically transformed cells, for GSTP1 was observed whereas APC, RARβ2, and RASSF1A showed a field effect up to 3 mm from the malignant core in three prostatectomy samples. Furthermore, for each case, different patterns of the field effect were observed. The field effect appeared most pronounced with RARβ2. In 11 prostatectomy samples in which a second focus of cancer was identified, cells harboring RARβ2 methylation extended a large distance away from the primary tumor in one sample. Bisulfite sequencing of RARβ2 confirmed the presence of epigenetic aberrations.CONCLUSIONS: This study quantifies previous observations of methylation in histologically negative samples and provides important assessment of field effects based on epigenetic events in cancer. These molecular approaches set the stage for consideration of such data in prospective trials for assessment of surgical margins and prediction of recurrence. Prostate 68: 152–160, 2008.Keywords
This publication has 20 references indexed in Scilit:
- RASSF1A promoter methylation is frequently detected in both pre‐malignant and non‐malignant microdissected prostatic epithelial tissuesThe Prostate, 2007
- Gene Promoter Methylation in Prostate Tumor–Associated Stromal CellsJNCI: Journal of the National Cancer Institute, 2006
- Epigenetic Heterogeneity of High-Grade Prostatic Intraepithelial Neoplasia: Clues for Clonal Progression in Prostate CarcinogenesisMolecular Cancer Research, 2006
- MGMT Promoter Methylation and Field Defect in Sporadic Colorectal CancerJNCI: Journal of the National Cancer Institute, 2005
- CpG island methylation and expression of tumour-associated genes in lung carcinomaEuropean Journal of Cancer, 2005
- Promoter Hypermethylation of Resected Bronchial MarginsClinical Cancer Research, 2004
- Quantitative Multiplex Methylation-Specific PCR Assay for the Detection of Promoter Hypermethylation in Multiple Genes in Breast CancerCancer Research, 2004
- QuantitativeRARβ2HypermethylationClinical Cancer Research, 2004
- Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancerNature Genetics, 2004
- Heterogeneous gene methylation patterns among pre‐invasive and cancerous lesions of the prostate: A histopathologic study of whole mount prostate specimensThe Prostate, 2004